SAFETY DATA SHEET



1. Identification

Product identifier Mounjaro™

Other means of identification

Item Code PS1462, PS3325, PS3516, PS3681, PS3837, PS4170, PS4043, 703550, 703551, 703552,

703553, 703554, 703555, 703561, 703562, 703563, 703570, 703571, 703572, PS1457, PS1460, PS1471, PS1484, PS1495, PS1506, 702212, 702211, 702210, 702186, 702187, 702188, 702220, 702216, 702215, 702214, 702213, 702200, 702197, 702196, 702195, 702194, 702193, 702192, 701410, 701626, 701053, 701622, 701052, 701624, 701599, 701598, CT9752, CT9751, CT9750,

CT9749, 701580, 701327, CT2085, 701010, CT9579, 700991, CT9578

Synonyms Tirzepatide Injection
Recommended use Pharmaceutical
Recommended restrictions None known.

Manufacturer/Importer/Supplier/Distributor information

Manufacturer

Company name Eli Lilly and Company
Address Lilly Corporate Center
Indianapolis, IN 46285

United States

Telephone Phone: +1-317-276-2000

E-mail lilly_sds@lilly.com

Emergency phone number CHEMTREC: +1-800-424-9300

2. Hazard(s) identification

Physical hazards Not classified.

Health hazards Not classified.

OSHA defined hazards Not classified.

Label elements

Hazard symbol None.
Signal word None.

Hazard statement The substance does not meet the criteria for classification.

Precautionary statement

Prevention Not available.

Response Not available.

Storage Not available.

Disposal Not available.

Hazard(s) not otherwise

classified (HNOC)

None known.

3. Composition/information on ingredients

Mixtures

Chemical name	Common name and synonyms	CAS number	%
Tirzepatide		2023788-19-2	1 - 3

Composition comments Remaining components of this product are non-hazardous and/or are present at concentrations

below reportable levels.

4. First-aid measures

Inhalation Remove to fresh air. If breathing stops, provide artificial respiration. Get medical attention

immediately.

Skin contact Wash off immediately with plenty of water for at least 15 minutes. Immediately take off all

contaminated clothing. Get medical attention if irritation develops and persists. Wash

contaminated clothing before reuse.

Eye contact Immediately flush eye(s) with plenty of water. Get medical attention.

 Material name: Mounjaro™
 sps us

 6758 Version #: 01 Issue date: 05-24-2022
 1 / 5

Ingestion Consult a physician.

Most important

symptoms/effects, acute and delayed

sugar. Symptoms typically associated with low blood sugar may include shakiness, sweating, fatigue, hunger, irritability, confusion, and rapid heartbeat.

Indication of immediate medical attention and special treatment needed

Provide general supportive measures and treat symptomatically. Symptoms may be delayed.

May cause nausea, decreased appetite, diarrhea, and vomiting. May cause decrease in blood

5. Fire-fighting measures

Suitable extinguishing media

Unsuitable extinguishing

media

Specific hazards arising from

Special protective equipment

the chemical

and precautions for firefighters

Carbon dioxide, dry chemical or water.

None known.

Hazardous decomposition products formed under fire conditions.

Wear self-contained breathing apparatus and protective clothing.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

Wear suitable protective clothing, gloves and eye/face protection. See Section 8 of the SDS for Personal Protective Equipment.

Methods and materials for containment and cleaning up Stop the flow of material, if this is without risk. Use absorbent/adsorbent material to solidify liquids.

Clean surface thoroughly to remove residual contamination.

Environmental precautions Avoid discharge into drains, water courses or onto the ground.

7. Handling and storage

Do not breathe mist or vapor. Avoid contact with eyes, skin, and clothing. See Section 8 of the Precautions for safe handling

SDS for Personal Protective Equipment.

Conditions for safe storage, including any incompatibilities Keep container tightly closed in a dry and well-ventilated place.

8. Exposure controls/personal protection

Occupational exposure limits

Lilly (LEG)

Components	Туре	Value
Tirzepatide (CAS 2023788-19-2)	TWA (12hrs)	60 ug/m3
·	TWA (8hrs)	90 ug/m3

Biological limit values No biological exposure limits noted for the ingredient(s). Health Based Excursion Limit: Maintain Full Shift TWA **Exposure guidelines**

Appropriate engineering

controls

Open handling is not recommended. Use appropriate control measures such as fume hood,

ventilated enclosure, local exhaust ventilation, or down-draft booth.

Individual protection measures, such as personal protective equipment

Eye/face protection Safety glasses with side shields recommended. If splash potential or dusty operations, wear

goggles/faceshield.

Skin protection

Hand protection Chemical resistant gloves.

Chemical-resistant gloves and impermeable body covering to minimize skin contact. Other

If the applicable occupational exposure level (OEL) is anticipated to be exceeded, wear an Respiratory protection

approved respirator with sufficient protection factor to control exposure below the OEL.

General hygiene Tirzepatide is an active pharmaceutical ingredient with a therapeutic dose in humans at or below 1 mg/day. considerations

9. Physical and chemical properties

Appearance

Physical state Liquid.

Aqueous Solution **Form** Color Clear. Colorless.

Odor Odorless

Material name: Mounjaro™ SDS US

Not available. Odor threshold Ha 6.5 - 7.5Melting point/freezing point Not available.

Initial boiling point and boiling Not available.

range

Flash point Not available. Not available. **Evaporation rate**

Flammability (solid, gas) No data available for this product.

Upper/lower flammability or explosive limits

Not available. Explosive limit - lower (%) Explosive limit - upper (%) Not available. Not available. Vapor pressure Vapor density Not available. Not available. Relative density

Solubility(ies)

Soluble. Solubility (water) Not available. Partition coefficient

(n-octanol/water)

Not available. **Auto-ignition temperature** Not available. **Decomposition temperature** Not available. Viscosity

Other information

Explosive properties Not explosive. **Oxidizing properties** Not oxidizing.

10. Stability and reactivity

Reactivity Not water reactive.

Material is stable under normal conditions. Chemical stability Possibility of hazardous

reactions

Hazardous polymerization does not occur.

Conditions to avoid Contact with incompatible materials.

Incompatible materials Strong oxidizing substances.

Hazardous decomposition

products

Hazardous decomposition products formed under fire conditions.

11. Toxicological information

Information on toxicological effects

Acute toxicity Not expected to be active orally.

Skin corrosion/irritation Due to lack of data the classification is not possible. Serious eve damage/eye Due to lack of data the classification is not possible.

irritation

Respiratory or skin sensitization

Due to lack of data the classification is not possible. Respiratory sensitization Due to lack of data the classification is not possible. Skin sensitization Negative In vivo micronucleus test: (Tirzepatide) Germ cell mutagenicity

Based on available data, the classification criteria are not met.

Not listed by IARC, NTP, ACGIH or OSHA. Carcinogenicity

In a 2-year carcinogenicity study in rats, Tirzepatide caused statistically significant dose-related increases in the incidence of thyroid C-cell tumors (adenomas and carcinomas combined) following twice weekly subcutaneous administration. The human relevance of these findings is currently unknown. Thyroid C-cell changes were not reported in monkeys or in a 6-month

carcinogenicity study in transgenic mice.

Based on available data, the classification criteria are not met.

IARC Monographs. Overall Evaluation of Carcinogenicity

Not listed.

Material name: Mounjaro™ SDS US OSHA Specifically Regulated Substances (29 CFR 1910.1001-1053)

Not listed.

US. National Toxicology Program (NTP) Report on Carcinogens

Not listed.

Reproductive toxicity Animal testing did not show any effects on fertility. Developmental effects have been reported at

doses toxic to the mother. (Tirzepatide)

Based on available data, the classification criteria are not met.

Specific target organ toxicity -

single exposure

No target organ toxicity identified through animal studies. (Tirzepatide)

Based on available data, the classification criteria are not met.

Specific target organ toxicity -

repeated exposure

No target organ toxicity identified through animal studies. (Tirzepatide)

Based on available data, the classification criteria are not met.

Aspiration hazard Not applicable.

May cause nausea, decreased appetite, diarrhea, and vomiting. May cause decrease in blood **Further information**

sugar. Symptoms typically associated with low blood sugar may include shakiness, sweating,

fatigue, hunger, irritability, confusion, and rapid heartbeat.

12. Ecological information

Due to lack of data the classification is not possible. **Ecotoxicity**

Readily biodegradable. (Tirzepatide) Persistence and degradability No data available on bioaccumulation. Bioaccumulative potential

Mobility in soil Not available. Not available. Other adverse effects

13. Disposal considerations

Disposal instructions Dispose in accordance with all applicable regulations.

14. Transport information

DOT

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Transport in bulk according to

Annex II of MARPOL 73/78 and

the IBC Code

Not available.

15. Regulatory information

This product is not known to be a "Hazardous Chemical" as defined by the OSHA Hazard US federal regulations

Communication Standard, 29 CFR 1910.1200.

Toxic Substances Control Act (TSCA)

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

CERCLA Hazardous Substance List (40 CFR 302.4)

Not listed.

SARA 304 Emergency release notification

Not regulated.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1053)

Not listed.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

SARA 313 (TRI reporting)

Not regulated.

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

Material name: Mounjaro™ SDS US Safe Drinking Water Act Not regulated.

(SDWA)

US state regulations

California Proposition 65

California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65): This material is not known to contain any chemicals currently listed as carcinogens or reproductive toxins. For more information go to www.P65Warnings.ca.gov.

International Inventories

Country(s) or region	Inventory name	On inventory (yes/no)*
Canada	Domestic Substances List (DSL)	No
Canada	Non-Domestic Substances List (NDSL)	No
United States & Puerto Rico	Toxic Substances Control Act (TSCA) Inventory	No

^{*}A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)

16. Other information, including date of preparation or last revision

05-24-2022 Issue date

Version # 01

List of abbreviations ACGIH: American Conference of Governmental Industrial Hygienists.

DOT: Department of Transportation (49 CFR 172.101).

IATA: International Air Transport Association. IARC: International Agency for Research on Cancer. IMDG Code: International Maritime Dangerous Goods Code.

LEG: Lilly Exposure Guideline. NTP: National Toxicology Program.

OSHA: Occupational Safety & Health Administration.

PEL: Permissible Exposure Limit. STEG: Short Term Exposure Guideline. TWA: Time Weighted Average Value.

Disclaimer As of the date of issuance, we are providing available information relevant to the handling of this

material in the workplace. All information contained herein is offered with the good faith belief that

it is accurate. THIS SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANT ABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature

which may accompany the finished product.

For additional information contact:

Eli Lilly and Company Hazard Communication +1-317-651-9533

Revision information Product and Company Identification: Alternate Trade Names

SDS US 6758 Version #: 01 Issue date: 05-24-2022 5/5

Material name: Mounjaro™

A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing